Clinical Trial

Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.

Study acronym: START-NET
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
There are several ways of personalizing PRRT (peptide receptor radionuclide treatment) in NEN (neuroendocrine neoplasia). Nevertheless, the current treatment regimen is not personalized. This trial aims to compare personalized PRRT to non-personalized PRRT in terms of safety, efficacy and resource demands in order to optimize treatment outcomes in an evidence-based manner in future.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-05-19; most recent amendment 2025-09-03.
Status change: Active, Not Recruiting → Recruiting 2024-08-19
Status change: Not Yet Recruiting → Active, Not Recruiting 2024-03-07
Trial Details
NCT Number NCT05387603
Lead Sponsor Lund University Hospital
Conditions Neuroendocrine Tumors
Enrollment 300 participants
Start Date 2022-11-01
Primary Completion 2026-10-01 (estimated)
Study Completion 2026-10-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-10